Relation between plasma ceramides and cardiovascular death in chronic heart failure: A subset analysis of the GISSI‐HF trial

Aims Ceramides exert several biological activities that may contribute to the pathophysiology of cardiovascular disease and heart failure (HF). The association between plasma levels of distinct ceramides (that have been previously associated with increased cardiovascular risk) and cardiovascular mor...

Full description

Saved in:
Bibliographic Details
Published in:ESC Heart Failure 2020-12, Vol.7 (6), p.3288-3297
Main Authors: Targher, Giovanni, Lunardi, Gianluigi, Mantovani, Alessandro, Meessen, Jennifer, Bonapace, Stefano, Temporelli, Pier Luigi, Nicolis, Enrico, Novelli, Deborah, Conti, Antonio, Tavazzi, Luigi, Maggioni, Aldo Pietro, Latini, Roberto
Format: Article
Language:English
Subjects:
Acute coronary syndromes
Biomarkers
Body mass index
Cardiovascular disease
Cardiovascular mortality
Ceramides
Chromatography
Creatinine
Diabetes
Ejection fraction
Heart failure
Hypertension
Hypotheses
Laboratories
Lipids
Morbidity
Mortality
Original
Original s
Plasma
Risk factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims Ceramides exert several biological activities that may contribute to the pathophysiology of cardiovascular disease and heart failure (HF). The association between plasma levels of distinct ceramides (that have been previously associated with increased cardiovascular risk) and cardiovascular mortality in patients with chronic HF has received little attention. Methods and results In a post hoc ancillary analysis of the Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca‐Heart Failure (GISSI‐HF; NCT00336336) trial, we randomly selected a sample of 200 ambulatory patients with chronic HF who died due to cardiovascular causes and 200 patients who were alive at the end of the trial (after a median follow‐up period of 3.9 years). We measured baseline plasma concentrations of six previously identified high‐risk ceramide species [Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1/20:0), Cer(d18:1/22:0), Cer(d18:1/24:0), and Cer(d18:1/24:1) and their individual plasma ratios with Cer(d18:1/24:0)]. Patients who died due to cardiovascular causes had significantly (P 
ISSN:2055-5822
2055-5822
DOI:10.1002/ehf2.12885